Filing Flows › Lyell Immunopharma (LYEL) › Q2 2025
Lyell Immunopharma (LYEL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Lyell Immunopharma (LYEL) reported revenue of $8K for the second quarter 2025 (Q2 2025), -38% from a year earlier and +14% from the quarter before.
Lyell Immunopharma, Q2 2025: revenue $8K (-38% year over year), net loss $42.7M, operating cash flow −$34.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8K | +14% | -38% |
| Operating profit | −$47.1M | — | — |
| Net earnings | −$42.7M | — | — |
| Operating cash flow | −$34.5M | — | — |
What changed
Revenue was $8K in Q2 2025, down 38% year over year and up 14% from the previous quarter.
Operating costs exceeded revenue by $47.1M, an operating margin of -589250.0%. Total costs fell 9% while revenue fell 38%. The quarter ended with a net loss of $42.7M, narrower than the previous quarter's $52.2M loss.
Operating cash flow was −$34.5M. Non-cash charges added back $3.1M of depreciation and amortization and $5.0M of share-based compensation. Capital expenditures of $168K exceeded it, leaving free cash flow of −$34.6M.
Questions
What was Lyell Immunopharma's revenue in the second quarter 2025?
Lyell Immunopharma (LYEL) reported revenue of $8K for the second quarter 2025 (Q2 2025), -38% from a year earlier and +14% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.